Sequence Bio, a Newfoundland and Labrador-based genomics and precision medicine company, is pleased to announce the appointment of Sam Rasty, Ph.D., as the company’s Chief Executive Officer.
Dr. Rasty joins Sequence Bio as a seasoned executive with a demonstrated record of strategic and operational excellence across multinational big pharma and small biotech companies.
“On behalf of Sequence Bio’s Board of Directors, I am thrilled to welcome Dr. Rasty to the team,” said Mark Dobbin, Chair of the Board. “Sam is a proven leader whose 25 years of experience in company building, strategic transactions and biopharma product development across multiple therapeutic areas uniquely position him to lead Sequence Bio through its next phases of growth,” added Mr. Dobbin.
“Sequence Bio is poised to make a significant difference in the lives of patients across the world while delivering benefits back to Newfoundland and Labrador,” said Dr. Rasty. He continued, “I am extremely excited to join the company at this important time as we continue to build the organization and work closely with external partners and key stakeholders to significantly advance the discovery and development of therapeutic drugs that address global unmet clinical needs.”
Consistent with the company’s transition plan, Lynn Healey, who served as Interim Chief Executive Officer, has resumed her position as Sequence Bio’s Chief Operating and Financial Officer.
“The board would like to thank Lynn for her leadership during this transition period. It is a testament to the remarkable dedication of her and the entire Sequence Bio team that we are able to welcome Dr. Rasty to the CEO role.” said Mark Dobbin.
Dr. Rasty is a seasoned Biotech executive with more than 25 years of experience in leadership roles spanning global large pharma, midcap pharma, and small, private biotech companies. His broad biopharma experience spans company formation and launch, new product planning, strategy formulation, fundraising, operations, R&D, manufacturing, corporate development and strategic marketing. He has led product development across multiple therapeutic areas and technology platforms spanning small molecules, biologics, medical devices, and gene and cell therapies.
He was most recently President and CEO of PlateletBio, a privately held cell therapy biotech company in Boston, Massachusetts. Prior to PlateletBio, he was Chief Operating Officer and employee #2 at Homology Medicines, a gene editing and gene therapy company in the Boston area, where he played a key role in launching and growing Homology from a private, discovery stage start-up to an established, clinical stage public biotech company. Before joining Homology, he held leadership positions at biopharma industry stalwarts including Shire PLC, where he served as Vice President and Head of New Products, Endo Pharmaceuticals, where he was Director of Corporate Development, and GlaxoSmithKline, where he served as Director of Portfolio Management and Global Commercial Strategy.
Dr. Rasty received a Ph.D. in Biochemistry from Louisiana State University, completed a postdoctoral fellowship in Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine and received his MBA from Villanova University in Philadelphia.
Sequence Bio is a genomics and precision medicine company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across disease indications of high unmet clinical need. Sequence Bio collaborates with the people of Newfoundland and Labrador and partners with the biopharma industry to help accelerate the development of new medicines for addressing unmet medical needs of patients across the globe.
VP, Market Development